These include lirilumab (1-7F9, IPH2101) targeting KIR2DL1, KIR2DL2, and KIR2DL3 in patients with AML, myeloma, or solid tumors in AML [47,48] and IPH4102, a first-in-class monoclonal antibody targeting KIR3DL2 in patients with cutaneous T-cell lymphoma, predominantly those with Sézary syndrome. Here, KIR2DL1 is linked to acute myeloid leukemia.